晚期非小细胞肺癌不同治疗方案疗效的比较

目的:通过对IIIb~IV期非小细胞肺癌(NSCLC)不同化疗方案的临床疗效及毒性分析,为临床用药提供指导。方法:95例IIIb~IV期非小细胞肺癌分为4组,NP组33例,NVB25mg/m2,iv,d1,8,CDDP30mg/m2,iv,d1~3;GP组26例,GEM1000mg/m2,iv,d1,8,CBP300mg/m2,iv,d1;TP组20例,Taxotere35mg/m2,iv,d1,8,15,CBP300mg/m2,iv,d1;NG组16例,NVB25mg/m2,iv,d1,8,GEM1000mg/m2,iv,d1,8.完成2周期治疗后评价疗效。结果:临床获益率分别为75.7%,92.3%,90%,81.2%,无明显差异(P=0.77)。生活质量改善率分别为30.3%,30.8%,45%,31.3%,无明显差异(P=0.844)。毒性反应III~IV度白细胞减少,血红蛋白减少,4组无明显差别(P=0.19,P=0.096);血小板减少,4组有显著差别(P=0.013);消化道反应NP组最明显(P<0.01)。结论:NVB CDDP,GEM CBP,Taxotere CBP,GEM NVB4个方案疗效近似,毒性反应各异,临床用药应因人而异,遵循个体化用药原则。

Comparison of different regimen in treatment of patients with advanced non-small cell lung cancer

Objective: To compare the efficacy and toxicity of four regimens for treatment of patients with IIIb~IV stage non-small cell lung cancer and provide the reference for clinic administration. Methods: A total of 95 patients were enrolled in this study,NP group 33 patients received NVB25mg/m~2,iv,d1,8,CDDP30mg/m~2,iv,d1~3;GP group 26 patients received GEM1000mg/m~2,iv,d1,8,CBP300mg/m~2,iv,d1; TC group 33 patients received taxotere35mg/m~2,iv,d1,8,15, CBP300mg/m~2,iv,d1;NG group 16 patients received NVB25mg/m~2,iv,d1,8,GEM1000mg/m~2,iv,d1,8.Effect was determed after two cycles treatment. Results: CBR of four groups were 75.7%,92.3%,90%,81.2%.There didn' t have significant difference(P=0.77). Amelioration ratio of quality of life were 30.3%,30.8%,45%,31.3%. There didn' t have significant differece(P=0.844). Side effects of III-IV degree: leucocytopenia, ferrohemoglobin decrease, thrombocytopenia were similar(P=0.19,P=0.096,P=0.013);NP group had significant differece with other groups in digestive system reaction. Conclusion: The clinical efficacy of NVB CDDP,GEM CBP,taxotere CBP,GEM NVB are similar, side effects are different. Clinical administration should be according to individualization doctrine.